Off-label use of omalizumab in non-asthma conditions: new opportunities.

  title={Off-label use of omalizumab in non-asthma conditions: new opportunities.},
  author={Jaymin Bhagwanji Morjaria and Riccardo Polosa},
  journal={Expert review of respiratory medicine},
  volume={3 3},
Allergic diseases are mediated by IgE and, hence, neutralizing IgE to attenuate type I hypersensitivity reactions may result in clinical benefits. This has been mainly established in several large pre- and postmarketing studies of the humanized monoclonal anti-IgE antibody, omalizumab, in patients with allergic asthma. In this patient population, omalizumab has been shown to have beneficial effects in subjective and objective outcome measures, as well as resulting in reductions in medication… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 89 references

Similar Papers

Loading similar papers…